IL-17A increases TNF-α-induced COX-2 protein stability and augments PGE2 secretion from airway smooth muscle cells: Impact on β2-adrenergic receptor desensitization

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 3, 2016, Pages 387-396

  Rumzhum, N N ^a   Patel, B S ^a   Prabhala, P ^a   Gelissen, I C ^a   Oliver, B G ^a,b   Ammit, A J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

cAMP; COX 2 protein stability; IL 17A; PGE 2; receptors adrenergic beta 2

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYCLOHEXIMIDE; CYCLOOXYGENASE 2; INTERLEUKIN 17; MESSENGER RNA; PROSTAGLANDIN E2; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR;

AIRWAY SMOOTH MUSCLE CELL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN STABILITY; UPREGULATION; BRONCHUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RESPIRATORY SYSTEM; SMOOTH MUSCLE CELL;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHI; CYCLIC AMP; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; MYOCYTES, SMOOTH MUSCLE; PROTEASOME INHIBITORS; PROTEIN STABILITY; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY SYSTEM; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957593363     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12810     Document Type: Article

References (38)

1. Chesné J, Braza F, Mahay G, Brouard S, Aronica M, Magnan A,. IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med 2014; 190: 1094-1101.
2. Caramori G, Adcock IM, Di Stefano A, Chung KF,. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 397-412.
3. McAleer JP, Kolls JK,. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 2014; 260: 129-144.
4. Brandt EB, Kovacic MB, Lee GB, Gibson AM, Acciani TH, Le Cras TD, et al., Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol 2013; 132: 1194-1204.
5. Essilfie AT, Simpson JL, Horvat JC, Preston JA, Dunkley ML, et al., Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog 2011; 7: e1002244.
6. Roos AB, Sethi S, Nikota J, Wrona CT, Dorrington MG, Sandén C, et al., Interleukin-17A promotes neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 428-437.
7. Lunding LP, Webering S, Vock C, Behrends J, Wagner C, Hölscher C, et al., Poly(inosinic-cytidylic) acid-triggered exacerbation of experimental asthma depends on IL-17A produced by NK cells. J Immunol 2015; 194: 5615-5625.
8. Trian T, Moir LM, Ge Q, Burgess JK, Kuo C, King NJ, et al., Rhinovirus-induced exacerbations of asthma: how is the {beta}2-adrenoceptor implicated? Am J Respir Cell Mol Biol 2010; 43: 227-233.
9. Van Ly D, Faiz A, Jenkins C, Crossett B, Black JL, McParland B, et al., Characterising the mechanism of airway smooth muscle β2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS One 2013; 8: e56058.
10. Alkhouri H, Rumzhum NN, Rahman MM, FitzPatrick M, de Pedro M, Oliver BG, et al., TLR2 activation causes tachyphylaxis to beta2-agonists in vitro and ex vivo: modelling bacterial exacerbation. Allergy 2014; 69: 1215-1222.
11. Rumzhum NN, Rahman MM, Oliver BG, Ammit AJ,. Sphingosine 1-phosphate increases COX-2 expression and PGE secretion: effects on beta-adrenergic receptor desensitization. Am J Respir Cell Mol Biol 2015; doi: 10.1165/rcmb.2014-0443OC
12. Sastre B, del Pozo V,. Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis. Mediators Inflamm 2012; 2012: 645383.
13. Johnson PR, McKay KO, Armour CL, Black JL,. The maintenance of functional activity in human isolated bronchus after cryopreservation. Pulm Pharmacol 1995; 8: 43-47.
14. Pang L, Knox AJ,. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997; 121: 579-587.
15. Kang Y-J, Mbonye UR, DeLong CJ, Wada M, Smith WL,. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007; 46: 108-125.
16. Haddad A, Flint-Ashtamker G, Minzel W, Sood R, Rimon G, Barki-Harrington L,. Prostaglandin EP1 receptor down-regulates expression of cyclooxygenase-2 by facilitating its proteasomal degradation. J Biol Chem 2012; 287: 17214-17223.
17. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME,. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE2. Arch Biochem Biophys 2000; 374: 325-333.
18. Brender S, Barki-Harrington L,. β1-Adrenergic receptor downregulates the expression of cyclooxygenase-2. Biochem Biophys Res Commun 2014; 451: 319-321.
19. Bradshaw LN, Zhong J, Bradbury P, Mahmassani M, Smith JL, Ammit AJ, et al., Estradiol stabilizes the 105-kDa phospho-form of the adhesion docking protein NEDD9 and suppresses NEDD9-dependent cell spreading in breast cancer cells. Biochim Biophys Acta 2011; 1813: 340-345.
20. Moutzouris JP, Che W, Ramsay EE, Manetsch M, Alkhouri H, Bjorkman AM, et al., Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion. Biochim Biophys Acta 2010; 1803: 416-423.
21. Manetsch M, Seidel P, Heintz U, Che W, Hughes JM, Ge Q, et al., TLR2 ligand engagement upregulates airway smooth muscle TNFalpha-induced cytokine production. Am J Physiol Lung Cell Mol Physiol 2012; 302: L838-L845.
22. Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DWP, Torphy TJ, et al., TNFα-induced secretion of RANTES and IL-6 from human airway smooth muscle cells: modulation by cAMP. Am J Respir Cell Mol Biol 2000; 23: 794-802.
23. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T,. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723-727.
24. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR,. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000; 20: 4265-4274.
25. Mbonye UR, Yuan C, Harris CE, Sidhu RS, Song I, Arakawa T, et al., Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008; 283: 8611-8623.
26. Hartupee J, Liu C, Novotny M, Li X, Hamilton T,. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007; 179: 4135-4141.
27. Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ,. IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J Allergy Clin Immunol 2004; 114: 958-964.
28. Henness S, van Thoor E, Ge Q, Armour CL, Hughes JM, Ammit AJ,. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am J Physiol 2006; 290: L1283-L1290.
29. Mbonye UR, Wada M, Rieke CJ, Tang HY, Dewitt DL, Smith WL,. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006; 281: 35770-35778.
30. Skaar JR, Pagan JK, Pagano M,. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov 2014; 13: 889-903.
31. Kawakami Y, Uchiyama K, Irie T, Murao M,. Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 1973; 6: 127-132.
32. Pavord ID, Tattersfield AE,. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345: 436-438.
33. Billington CK, Ojo OO, Penn RB, Ito S,. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther 2013; 26: 112-120.
34. Shore SA, Moore PE,. Regulation of beta-adrenergic responses in airway smooth muscle. Respir Physiol Neurobiol 2003; 137: 179-195.
35. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A,. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-369.
36. Birrell MA, Maher SA, Buckley J, Dale N, Bonvini S, Raemdonck K, et al., Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol 2013; 168: 129-138.
37. Maher SA, Birrell MA, Adcock JJ, Wortley MA, Dubuis ED, Bonvini SJ, et al., Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events. Eur Respir J 2015; 45: 1108-1118.
38. Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, et al., Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax 2015; 70: 740-747.